Psyched Wellness Ltd C.PSYC

Psyched Wellness Announces Key Findings

[Betteryear2]

Toronto, Ontario--(Newsfile Corp. - April 26, 2022) - Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: DCNPF) (formerly Duncan Park Holdings Corporation) (the "Company" or "Psyched"), a life sciences company focused on the production and distribution of health and wellness products derived from the Amanita Muscaria mushroom , is pleased to announce the company KGK, a licensed CRO in Canada, has reported recent findings from the analysis of the intestinal epithelial immune receptor expression study performed in conjunction with the 90-day oral toxicity study with Amanita Muscaria Extract (AME-1). The in vivo study via oral supplementation with AME-1 focused on the potential bioactive effects on the immune receptors Toll-like Receptor-2 (TLR-2) and Dectin-1, both of which are found on the surface of gut epithelial cells. The Toll-like receptors are an important family within the innate immune system and play a vital role in host-defense mechanisms against pathogens. The main function of TLRs is the ability to recognize numerous pathogens, thus activating the host-defense mechanism through the induction of antimicrobial activity. Dectin-1 is a cell surface pathogen recognition receptor that recognizes soluble and /or particulate forms of β-1,3 or β-1,6-glucans and, like Toll-like receptors, plays an important role in the host-defense mechanism as well.

Psyched Wellness Announces Key Findings from the 90-Day Oral Toxicity Study on AME-1